Precision Medicine Initiative Aims High But Must Surmount Technical, Practical Hurdles
Executive Summary
White House proposal for a longitudinal cohort encompassing one million people seeks to leverage ongoing studies. But bringing all that data together under one roof, and ensuring it is useful and participants’ privacy is adequately protected, promises to be a significant task.
You may also be interested in...
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.
Lung-MAP Patient Screening Should Translate To Cost-Savings
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.